Study #2021-0033
Evaluation of talazoparib, a PARP inhibitor, in patients with somatic BRCA mutant metastatic breast cancer: genotyping based clinical trial
MD Anderson Study Status
Enrolling
Treatment Agent
Talazoparib
Description
This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Cancer
Study phase:
Phase II
Physician name:
Senthil Damodaran
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-877-909-0599
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.